How to Help Your Patients Find Vyleesi in Stock: A Provider's Guide

When you prescribe Vyleesi (bremelanotide) to a patient with hypoactive sexual desire disorder (HSDD), your clinical work is done — but the patient's journey to actually getting the medication has often just begun. The specialty pharmacy-only distribution model, insurance prior authorization requirements, and high cash costs create a complex access gauntlet that many patients navigate alone.

This guide gives you the clinical tools and workflow tips to reduce friction for your patients and improve the likelihood they'll actually receive and use the medication you've prescribed.

Step 1: Use the Correct Prescribing Workflow

The most common reason patients fail to receive Vyleesi is incorrect prescription routing. Standard retail pharmacies cannot fill Vyleesi prescriptions. Your prescription must be e-prescribed to the Vyleesi-designated specialty pharmacy network.

Here's the correct prescribing workflow:

1. E-prescribe Vyleesi (1.75 mg/0.3 mL autoinjector) directly to the exclusive specialty pharmacy network (search for "Vyleesi" in your EHR's e-prescribing directory to find the approved pharmacy).
2. Include the ICD-10 code F52.0 (hypoactive sexual desire disorder) in your prescription — this is the correct code for PA purposes.
3. The specialty pharmacy will contact the patient directly to collect insurance information, coordinate PA if needed, and arrange delivery or pickup.
4. Inform your patient to expect a call from an unfamiliar number — this is the specialty pharmacy, and missing the call can delay access.

Step 2: Document Thoroughly for Prior Authorization

The quality of your clinical documentation directly impacts PA approval speed and success rates. Insurers reviewing Vyleesi PAs want to see:

• Confirmed diagnosis of acquired, generalized HSDD (F52.0) — "acquired" means it developed after previously normal sexual desire; "generalized" means it occurs regardless of partner or situation
• Documentation of patient-reported distress or interpersonal difficulty attributable to low desire
• Exclusion of medical, psychiatric, relational, or drug-induced causes
• Confirmation of premenopausal status
• Absence of contraindications (uncontrolled hypertension, cardiovascular disease)

Consider using a validated tool such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS) to document baseline desire and distress scores. These objective measures significantly strengthen PA submissions and are useful for tracking response at follow-up.

Step 3: Enroll Patients in the Manufacturer's Copay Program at the Visit

For commercially insured patients, Cosette Pharmaceuticals offers the BlinkRx Copay Assistance program. Eligible patients can pay as little as $0 per fill. Some practices proactively enroll patients through the specialty pharmacy during the prescribing workflow — the specialty pharmacy may automatically ask about copay assistance during the patient intake call.

At the visit, simply tell the patient: "When the specialty pharmacy calls you, ask about the manufacturer copay assistance program — it can bring your out-of-pocket cost to $0." Provide the number: 1-833-799-5028, or direct them to vyleesi.com/getting-started.

Important: this program is for commercially insured patients only. Patients on Medicaid, TRICARE, or Medicare are not eligible.

Step 4: Counsel Patients on What to Expect

Patients who are well-prepared for the Vyleesi access and side effect experience are more likely to persist through the initial challenges. Key counseling points:

• Expect a call from the specialty pharmacy — don't ignore it, even if the number is unfamiliar
• Nausea is common with the first dose (about 40%) but usually improves with subsequent uses
• Inject at least 45 minutes before anticipated sexual activity, into the abdomen or thigh
• No alcohol restriction (unlike Addyi)
• Limit to 1 dose per 24 hours and 8 doses per month
• Advise women of childbearing potential to use contraception while on Vyleesi

Step 5: Use medfinder If the Prescription Gets Stuck

When patients report that the specialty pharmacy isn't responding, the prescription is in limbo, or they've been unable to locate a pharmacy that can fill it in their area, medfinder for providers offers a streamlined way to identify which pharmacies near the patient can fill the prescription — without your staff spending time on the phone.

Monitoring and Follow-Up

At follow-up (typically 4–8 weeks), reassess desire scores and distress levels. Document improvement to support reauthorization. If the patient reports persistent intolerable nausea, consider discontinuation or anti-emetic co-therapy. If Vyleesi proves ineffective, discuss alternatives. Read our full provider briefing on Vyleesi access challenges in 2026 for additional clinical context.